Provided by Tiger Trade Technology Pte. Ltd.

Tredegar

7.78
-0.1500-1.89%
Post-market: 7.780.00000.00%19:30 EDT
Volume:114.88K
Turnover:891.54K
Market Cap:271.61M
PE:8.13
High:7.92
Open:7.89
Low:7.67
Close:7.93
52wk High:10.53
52wk Low:6.25
Shares:34.91M
Float Shares:28.88M
Volume Ratio:0.62
T/O Rate:0.40%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.9572
EPS(LYR):0.9604
ROE:15.47%
ROA:6.50%
PB:1.19
PE(LYR):8.10

Loading ...

TG-17 Schedules CEO-Led Investor Webinar for June

TIPRANKS
·
Jun 17

TG-17 Restructures Capital and Leadership to Support Growth

TIPRANKS
·
Jun 16

Major Tredegar Insiders Quietly Unload a Chunk of Shares in Near-Identical Trades

TIPRANKS
·
Jun 16

Tredegar 10% owner James T. Gottwald sells 26,298 shares worth $213,783.27

Reuters
·
Jun 16

TG Therapeutics Shareholders Reject Executive Compensation at Meeting

TIPRANKS
·
Jun 13

Major Insider Trio Makes Synchronized Exit Move in Tredegar Stock

TIPRANKS
·
Jun 12

Tredegar 10% owner James T. Gottwald disposes of USD 146,820 in common shares

Reuters
·
Jun 12

Tredegar 10% owner John D. Gottwald sells 18,159 shares for $145,351.53

Reuters
·
Jun 12

A Look At TG Therapeutics (TGTX) Valuation After Fresh BRIUMVI Clinical And Formulation Milestones

Simply Wall St.
·
Jun 10

TG Therapeutics: Buy Rating Reiterated on Briumvi Expansion Strategy, $70 Price Target Unchanged

TIPRANKS
·
Jun 09

Major Insider Trio Quietly Trims Tredegar Holdings in Synchronized Stock Moves

TIPRANKS
·
Jun 09

Tredegar 10% owner James T. Gottwald disposes of 3,367 common shares worth $26,668.08

Reuters
·
Jun 09

Tredegar 10% owner James T. Gottwald sells 1,044 shares for $8,184.19

Reuters
·
Jun 05

Analysts Offer Insights on Healthcare Companies: CVS Health (CVS), TG Therapeutics (TGTX) and Dexcom (DXCM)

TIPRANKS
·
Jun 04

B. Riley Securities Remains a Buy on TG Therapeutics (TGTX)

TIPRANKS
·
Jun 04

TG Therapeutics rises 10.6%

TIPRANKS
·
Jun 04

Analysts’ Top Healthcare Picks: TG Therapeutics (TGTX), AbbVie (ABBV)

TIPRANKS
·
Jun 03

TG Therapeutics Reports Positive Phase 1 Data for Subcutaneous Multiple Sclerosis Therapy

MT Newswires Live
·
Jun 03

TG Therapeutics announces results from Briumvi trial

TIPRANKS
·
Jun 03

TG Therapeutics reports positive data for subcutaneous BRIUMVI

TIPRANKS
·
Jun 03